Strok: Perbedaan antara revisi

Konten dihapus Konten ditambahkan
ESCa (bicara | kontrib)
ESCa (bicara | kontrib)
Baris 378:
 
== Penanganan ==
Penderita strok akut biasanya diberikan SM-20302,<ref>{{en}}{{cite web
Penderita strok akut biasanya diberikan [[oksigen]], dipasang [[infus]] untuk memasukkan cairan dan zat makanan, kemudian diberikan [[manitol]] atau [[kortikosteroid]] untuk mengurangi pembengkakan dan tekanan di dalam otak,<ref>{{id}} {{cite web|last = Misbach|first = H Jusuf|authorlink =|coauthors = Harmani Kalim|year =|url = http://medicastore.com/stroke/Penanganan_Stroke.php|title = Penanganan Stroke|format =|work =|publisher = Medicastore|accessdate = 13 November|accessyear = 2010|archiveurl =|archivedate =|quote =}}</ref> akibat infiltrasi [[sel darah putih]]. Penelitian terakhir menunjukkan bahwa kelumpuhan dan gejala lainnya bisa dicegah atau dipulihkan jika [[recombinan]] ''tissue plasminogen activator'' (RTPA) atau [[streptokinase]] yang berfungsi menghancurkan [[emboli]] diberikan dalam waktu 3 jam setelah timbulnya strok.
| url = http://www.ncbi.nlm.nih.gov/pubmed/11779904
| title = The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
| accessdate = 2011-09-08
| work = Department of Neuroscience, University of California at San Diego; Lapchak PA, Araujo DM, Song D, Zivin JA.
}}</ref> atau ''microplasmin'',<ref>{{en}}{{cite web
| url = http://www.ncbi.nlm.nih.gov/pubmed/12215599
| title = Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
| accessdate = 2011-09-08
| work = Department of Neuroscience, University of California at San Diego; Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA.
Penderita strok akut biasanya diberikan}}</ref> [[oksigen]], dipasang [[infus]] untuk memasukkan cairan dan zat makanan, kemudian diberikan [[manitol]] atau [[kortikosteroid]] untuk mengurangi pembengkakan dan tekanan di dalam otak,<ref>{{id}} {{cite web|last = Misbach|first = H Jusuf|authorlink =|coauthors = Harmani Kalim|year =|url = http://medicastore.com/stroke/Penanganan_Stroke.php|title = Penanganan Stroke|format =|work =|publisher = Medicastore|accessdate = 13 November|accessyear = 2010|archiveurl =|archivedate =|quote =}}</ref> akibat infiltrasi [[sel darah putih]]. Penelitian terakhir menunjukkan bahwa kelumpuhan dan gejala lainnya bisa dicegah atau dipulihkan jika [[recombinan]] ''tissue plasminogen activator'' (RTPArtPA) atau [[streptokinase]] yang berfungsi menghancurkan [[emboli]] diberikan dalam waktu 3 jam,<ref>{{en}}{{cite setelah timbulnya strok.web
| url = http://www.ncbi.nlm.nih.gov/pubmed/7477192
| title = Tissue plasminogen activator for acute ischemic stroke.
| accessdate = 2011-09-08
| work = The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
}}</ref> setelah timbulnya strok. [[Trombolisis]] dengan rtPA terbukti bermanfaat pada manajemen strok akut, walaupun dapat meningkatkan risiko pendarahan otak,<ref>{{en}}{{cite web
| url = http://www.ncbi.nlm.nih.gov/pubmed/11700147
| title = Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.
| accessdate = 2011-09-08
| work = Department of Neuroscience, University of California San Diego; Lapchak PA, Araujo DM.
}}</ref> terutama pada area sawar darah otak yang terbuka.<ref>{{en}}{{cite web
| url = http://www.ncbi.nlm.nih.gov/pubmed/12154270
| title = Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model.
| accessdate = 2011-09-08
| work = Neuroprotection Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School,; Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH.
}}</ref>
 
Beberapa senyawa yang diberikan bersamaan dengan rtPA untuk mengurangi risiko tersebut antara lain [[batimastat]] (BB-94) dan [[marimastat]] (BB-2516),<ref>{{en}}{{cite web
| url = http://www.ncbi.nlm.nih.gov/pubmed/9195290
| title = Matrix metalloproteinase inhibitors.
| accessdate = 2011-09-08
| work = Georgetown University Hospital, Vincent T. Lombardi Cancer Center, Division of Medical Oncology; Wojtowicz-Praga SM, Dickson RB, Hawkins MJ.
}}</ref> yang menghambat [[enzim]] MMP, senyawa ''spin trap agent'' seperti ''alpha-phenyl-N-t-butylnitrone'' (PBN) dan ''disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide'' (NXY-059),<ref>{{en}}{{cite web
| url = http://www.ncbi.nlm.nih.gov/pubmed/12053009
| title = Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
| accessdate = 2011-09-08
| work = Department of Neuroscience, University of California at San Diego; Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA.
}}</ref> dan senyawa anti-ICAM-1.<ref>{{en}}{{cite web
| url = http://www.ncbi.nlm.nih.gov/pubmed/10066862
| title = Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.
| accessdate = 2011-09-08
| work = Department of Neurology, Henry Ford Health Sciences Center; Zhang RL, Zhang ZG, Chopp M, Zivin JA.
}}</ref>
 
Metode perawatan [[hemodilusi]] dengan menggunakan [[albumin]] masih kontroversial,<ref>{{en}} {{cite web